• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Edema in heart disease].

作者信息

Muto Shinsuke, Hirata Yasunobu

机构信息

Department of Cardiovascular Medicine, University of Tokyo, Graduate School of Medicine.

出版信息

Nihon Rinsho. 2005 Jan;63(1):68-72.

PMID:15675320
Abstract

The two main causes of cardiac edema are congestive heart failure and pericardial diseases. Careful evaluation of patients with edema is important because there are many other diseases showing the symptom. Important for the treatment of edema is to restrict sodium and water intake. Diuretics and digoxin have formed the mainstay of treatment for many years. Patients with edema should be given diuretics until an euvolemic state is achieved. Especially loop diuretic is effective to reduce edema quickly. Recently atrial natriuretic peptide and brain natriuretic peptide are shown to be useful markers to assess heart failure. These peptides are also useful as therapeutic tools for treating edema in heart failure. Even if the patient has responded favorably to diuretics, angiotensin converting enzymes inhibitors, angiotensin II receptor blockers, beta blockers and spironolactone should be added according to the status, because there are many evidences that they improve the long-term prognosis. Vasopeptidase inhibitors and vasopressin antagonist are being introduced for management of heart failure.

摘要

相似文献

1
[Edema in heart disease].
Nihon Rinsho. 2005 Jan;63(1):68-72.
2
Pathophysiology of edema in congestive heart failure.充血性心力衰竭中水肿的病理生理学
Heart Dis Stroke. 1993 Jul-Aug;2(4):325-9.
3
Edema mechanisms in the patient with heart failure and treatment options.心力衰竭患者的水肿机制及治疗选择。
Heart Fail Clin. 2008 Oct;4(4):511-8. doi: 10.1016/j.hfc.2008.04.002.
4
Edematous disorders: pathophysiology of renal sodium and water retention and treatment with diuretics.水肿性疾病:肾钠水潴留的病理生理学及利尿剂治疗
Curr Opin Nephrol Hypertens. 1993 Sep;2(5):798-805.
5
[Progress in management for heart failure: diuretics].[心力衰竭的管理进展:利尿剂]
Nihon Rinsho. 1993 May;51(5):1281-6.
6
Treatment of edema.水肿的治疗。
Am Fam Physician. 2005 Jun 1;71(11):2111-7.
7
[Trends in pharmacological treatment of congestive heart failure].[充血性心力衰竭的药物治疗趋势]
Pol Merkur Lekarski. 1999 Mar;6(33):152-6.
8
[Natriuretic peptides--new diagnostic markers in heart disease].[利钠肽——心脏病的新型诊断标志物]
Herz. 2004 Sep;29(6):609-17. doi: 10.1007/s00059-004-2619-8.
9
Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure.利钠肽:心力衰竭中的生物化学、生理学及治疗作用
Heart Dis. 2003 May-Jun;5(3):215-23. doi: 10.1097/01.HDX.0000074517.30102.64.
10
Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.醛固酮受体拮抗在心力衰竭中的心脏保护作用。第一部分。醛固酮在心力衰竭中的作用。
Fiziol Cheloveka. 2005 Nov-Dec;31(6):97-105.